Patent US4695590A successfully refreshed from Google Patents.
US4695590A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for retarding aging
Assignee: UCB Inc
•
Filing: 1986-05-05
•
Granted: 1987-09-22
•
Expires: 2006-05-05
Abstract
Abstract Methods and compositions are provided for retarding aging, i.e., inhibiting damage to human cells caused by toxic byproducts of oxygen metabolism. The anti-aging active ingredient is a compound or mixture of compounds represented by the following structural formula: <IMAGE> (1) wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represent hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof.
Inventors
- 👤 Richard D. Lippman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 18:05
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/045; A61K31/05; A61K31/055; A61P; A61P17/00; A61P43/00
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
143 words
A method for retarding aging in humans by administering to a human a daily dosage of from about 0.5 mg per kilogram of body weight to less than about 2 mg per kilogram of body weight of a pharmaceutically acceptable composition comprising a compound or a mixture of compounds represented by the following structural formula: ##STR6## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof.
Claim 2
Independent Claim
143 words
A method for retarding aging in humans by administering to a human a daily dosage of from about 0.5 mg per kilogram of body weight to less than about 2 mg per kilogram of body weight of a pharmaceutically acceptable composition comprising a compound or a mixture of compounds represented by the following structural formula: ##STR6## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof.
Claim 3
Dependent Claim
12 words
The method according to claim 1 wherein the compound is nordihydroguairetic acid.
Claim 4
Dependent Claim
11 words
The method according to claim 1 wherein the compound is bis(p-hydroxyphenyl)methane.
Claim 5
Dependent Claim
12 words
The method according to claim 1 wherein the composition is administered orally.
Claim 6
Dependent Claim
25 words
The method according to claim 1 wherein the composition is administered by a means selected from the group consisting of intravenously, subcutaneously, intramuscularly and intracutaneously.
Claim 7
Dependent Claim
136 words
A pharmaceutical composition in solid dosage form for retarding aging in humans consisting essentially of a compound or mixture of compounds represented by the following structural formula as the active ingredient: ##STR7## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof, wherein from about 20 mg to 100 mg of said active ingredient is present in the composition.
Claim 8
Dependent Claim
136 words
A pharmaceutical composition in solid dosage form for retarding aging in humans consisting essentially of a compound or mixture of compounds represented by the following structural formula as the active ingredient: ##STR7## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof, wherein from about 20 mg to 100 mg of said active ingredient is present in the composition.
Claim 9
Dependent Claim
14 words
A composition as is claimed in claim 6 wherein the compound is nordihydroguairetic acid.
Claim 10
Dependent Claim
13 words
A composition as is claimed in claim 6 wherein the compound is bis(p-hydroxyphenyl)methane.
Claim 11
Dependent Claim
130 words
A pharmaceutical composition for topical administration to the skin of a human consisting essentially of an effective amount of a compound or mixture of compounds represented by the following structural formula as the only active ingredient in a topical pharmaceutically acceptable carrier: ##STR8## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof.
Claim 12
Dependent Claim
130 words
A pharmaceutical composition for topical administration to the skin of a human consisting essentially of an effective amount of a compound or mixture of compounds represented by the following structural formula as the only active ingredient in a topical pharmaceutically acceptable carrier: ##STR8## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 and R3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof.
Claim 13
Dependent Claim
14 words
A composition as is claimed in claim 9 wherein the compound is nordihydroguairetic acid.
Claim 14
Dependent Claim
13 words
A composition as is claimed in claim 9 wherein the compound is bis(p-hydroxyphenyl)methane.
Claim 15
Dependent Claim
31 words
A composition as is claimed in claim 10 wherein the composition contains from about 0.5% to about 20% by weight of nordihydroguairetic acid compared to the total weight of the composition.
Claim 16
Dependent Claim
148 words
A pharmaceutical composition for topical administration to the skin of a human consisting essentially of a compound or mixture of compounds represented by the following structural formula as the acitve ingredient in a topical pharmaceutically acceptable carrier, wherein the composition contains from about 0.5% to about 20% by weight of the active ingredient compared to the total weight of the composition: ##STR9## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 andR3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof.
Claim 17
Dependent Claim
148 words
A pharmaceutical composition for topical administration to the skin of a human consisting essentially of a compound or mixture of compounds represented by the following structural formula as the acitve ingredient in a topical pharmaceutically acceptable carrier, wherein the composition contains from about 0.5% to about 20% by weight of the active ingredient compared to the total weight of the composition: ##STR9## wherein m is 0, 1 or 2; n is 0 or 1; R1 is hydrogen, halogen or hydroxy; and R2 andR3 each independently represents hydrogen or methyl provided that when m is 0, n is 0 and when m is 1 or 2, n is 1 and R1 is hydroxy or halogen and that when m is 2, each R2 can be the same or different and each R3 can be the same or different or a pharmaceutically acceptable alkali or alkaline earth metal salt thereof.
Claim 18
Dependent Claim
14 words
A composition as is claimed in claim 13 wherein the compound is nordihydroguairetic acid.
Claim 19
Dependent Claim
13 words
A composition as is claimed in claim 13 wherein the compound is bis(p-hydroxyphenyl)methane.
Claim 20
Dependent Claim
31 words
A composition as is claimed in claim 14 wherein the composition contains from about 0.5% to about 20% by weight of nordihydroguairetic acid compared to the total weight of the composition.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-09-21 | 1991-03-23 | 1991-09-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-09-21 | 1995-03-23 | 1995-09-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-09-21 | 1999-03-23 | 1999-09-22 | $7700.00 | Window Closed / Lapsed |